ClinicalTrials.gg
RecruitingNCT07942207SRCNAUpdated Nov 17, 2026

Spanish Registry of Cardioneuroablation

An observational study in Syncope Recurrent, Syncope, Vasovagal, Neurally-Mediated and Cardioneuroabaltion, sponsored by Fundación de investigación HM. Recruiting at 27 sites in Spain. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Fundación de investigación HM · Observational

How we know

From the registry’s dates

  • Started Jun 2018; still recruiting 8 years 5 months later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Sex
All
01

Study summary

Spanish multicenter registry of cardioneuroablation (ablation of cardiac ganglionated plexi) in patients with reflex syncope and functional bradyarrhythmias Background Cardioneuroablation (CNA) is the catheter ablation of the ganglionated plexi (GP) of the intrinsic cardiac autonomic nervous system, located in the atrial epicardial fat, to reduce parasympathetic tone on the sinus node and the atrioventricular (AV) node. It has been proposed as an alternative to pacemaker implantation in patients, often young, with cardioinhibitory reflex syncope or vagally mediated bradyarrhythmias. However, the available evidence comes mainly from single-center series at highly experienced centers, with heterogeneous techniques (choice of atrium, number of GP targeted, localization method, type of anesthesia) and no standardized acute procedural endpoint. Data from real-world clinical practice are needed to define its efficacy and safety, and to identify which patients and which procedural strategies are associated with better outcomes.

Objectives Primary: to assess syncope recurrence after CNA in real-world clinical practice in Spain.

Secondary: 1) to describe the procedural characteristics and complications of CNA; 2) to identify clinical and procedural predictors of success; 3) to evaluate the change in syncope and presyncope burden and the need for pacemaker implantation during follow-up.

Design Observational, multicenter, ambispective, ongoing registry with 27 participating hospitals in Spain. Cases performed since June 2018 are collected retrospectively, and prospective enrollment of consecutive patients has been in place since April 2021.

Study population

Inclusion criteria: consecutive patients undergoing CNA for syncope with one of the following phenotypes:

  • Cardioinhibitory reflex syncope: bradycardia \<40 bpm or asystole documented on tilt testing, Holter monitoring or implantable loop recorder.
  • Mixed reflex syncope: blood pressure drop preceding the heart rate drop on tilt testing.
  • Functional sinus node dysfunction.
  • Functional AV block. Procedure

CNA is performed according to the usual practice of each center. The operator chooses:

  • the approach (right atrium, left atrium or both);
  • the number of GP targeted;
  • the GP localization method (anatomical, fragmented electrograms, high-frequency stimulation, extracardiac vagal stimulation or combinations);
  • the type of anesthesia (general anesthesia, deep sedation, conscious sedation). Data collected
  • Baseline: demographics, body mass index, cardiovascular history and structural heart disease, type of syncope, number of syncopal and presyncopal episodes before CNA, and diagnostic tests (tilt testing, Holter, implantable loop recorder, atropine test).
  • Procedural: approach, GP targeted, localization method, type of anesthesia, ablation catheter and navigation system, RF power and number of applications, procedure and fluoroscopy times, heart rate before and after CNA and response to atropine after the procedure.
  • Safety: procedure-related complications, including sinus node dysfunction, inappropriate sinus tachycardia and vascular complications.
  • Follow-up: syncope and presyncope recurrence, number of episodes per year, need for pacemaker implantation and other clinical events.

Endpoints Primary endpoint: first syncope recurrence after CNA. Secondary endpoints: procedure-related complications; number of syncopal and presyncopal episodes per year before and after CNA; pacemaker implantation during follow-up.

Ongoing sub-studies:

  1. long-term follow-up of these patients and identification of predictors of recurrence;
  2. redo procedures, in patients requiring more than one CNA;
  3. patients followed with an implantable loop recorder (subcutaneous Holter). Expected relevance This registry will provide multicenter real-world data on CNA in Spain. It will help to identify the patients most likely to benefit from the procedure and the technical aspects associated with success, and will generate hypotheses for future randomized trials.
02

Conditions studied

  • Syncope Recurrent
  • Syncope, Vasovagal, Neurally-Mediated
  • Cardioneuroabaltion

Browse trials for

03

In context

Syncope, Vasovagal

89 studies on the registry are indexed under Syncope, Vasovagal; 29 are open to participants now.

This study's planned enrollment of 400 is above the median of 140 across 30 observational studies indexed under Syncope, Vasovagal.

Browse Syncope, Vasovagal studies →

Lead sponsor

Fundación de investigación HM is the lead sponsor of 23 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients treated with cardioneuroablation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients treated with cardioneuroablation

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Interventions

  • Procedurecardioneuroablation

    cardioneuroablation

06

What researchers measure

Primary outcomes

  1. syncope

    recurrence of syncope

    Time frame: From the procedure (cardioneurobation) to short-term follow up (3 months) and long term follow up (one-year recurrence, 2- year, 3-year and 4-year recurrence)

Secondary outcomes

  1. Complications

    Complications

    Time frame: During procedure and 3 months after

07

Study locations

27 of 27 sites recruiting
08

References and documents

Publications

  • Barrio-Lopez MT, Alvarez-Ortega C, Minguito-Carazo C, Franco E, Garcia-Granja PE, Alcalde-Rodriguez O, Salvador-Montanes O, Francisco-Pascual J, Macias-Ruiz R, Marco Del Castillo A, Giacoman-Hernandez S, Exposito-Garcia V, Garcia-Izquierdo E, Manuel Duran J, Calvo-Galiano N, Luis Ibanez-Criado J, Garcia-Cuenca E, Calero S, Fernandez-Portales J, Linhart M, Rodriguez-Manero M, Martinez-Alday JD, Sanchez-Quintana D, Almendral-Garrote J, Moya-Mitjans A. Predictors of Clinical Success of Cardioneuroablation in Patients With Syncope: Results of a Multicenter Study. JACC Clin Electrophysiol. 2024 Dec;10(12):2711-2724. doi: 10.1016/j.jacep.2024.07.027. Epub 2024 Oct 23. PubMed 39453292 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2018 (actual). Primary completion is estimated for Dec 2030, 150 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 17, 2026
StartActual
Jun 1, 2018
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2031
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942207
Lead sponsor
Fundación de investigación HM
Responsible party
Teresa Barrio (MD PhD, Fundación de investigación HM) — Principal investigator
First posted
Nov 17, 2026
Start date
Jun 1, 2018
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Nov 17, 2026

Study contacts

Maria T Barrio-Lopez, MD PhD
Contact
terebarriol@gmail.com
+34 655298270
Jesus Almendral
Contact
almendraljesus@gmail.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion